Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.

Literature DB >> 23649292

Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.

Sarah Payton.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 23649292 DOI： 10.1038/nrurol.2013.100

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

2 in total

1. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Authors: Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini
Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316

2. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.

Authors: D Cella; B Escudier; B Rini; C Chen; H Bhattacharyya; J Tarazi; B Rosbrook; S Kim; R Motzer
Journal: Br J Cancer Date: 2013-04-11 Impact factor: 7.640

2 in total

1 in total

Review 1. Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

Authors: Elena Verzoni; Paolo Grassi; Isabella Testa; Roberto Iacovelli; Pamela Biondani; Enrico Garanzini; Filippo De Braud; Giuseppe Procopio
Journal: Pharmgenomics Pers Med Date: 2014-03-27

1 in total